CBLB and neoplasm: Nurix developed a Cbl-b inhibitor (NX-0255) intended for use in conjunction with adoptive T-cell therapy, known as drug-enhanced tumor-infiltrating lymphocyte (DeTIL) therapy, which is a combination therapy.